The abstract is read at the publisher; the summary is JClub's.
Silencing p50 NF-κB in the hematopoietic compartment (p50fl/flTie2-Cre mice) impairs cancer stem cell development, migration, and EMT, linked to reduced tumor aggressiveness.
- Why it matters: Current therapies lack approved CSC-eliminating options, and the role of existing treatments in shaping tumor stemness and therapy resistance remains unclear.
- What they did: In fibrosarcoma and melanoma mouse models, the study tested p50 NF-κB silencing and immune polarization, then evaluated anti-PD-1, anti-IFN-γ, anti-IL-4, high-dose IFN-γ, and combinations with doxorubicin.
- The result: Anti-PD-1 reduced CSC and tumor development with increased IFN-γ, while anti-IFN-γ restored growth and dissemination; anti-IL-4 enhanced immunotherapy and, with high-dose IFN-γ, limited stemness even alongside doxorubicin.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.